Browse treatments

…Background Despite advances in immunotherapy, durable patient responses remain a minority. This is partly du…

…ite remarkable results for many patients, the response rate for immunotherapy varies from one patient to the next. While technological advanc…

…lly morbid toxicities, occurring in ~1-8% of patients receiving immunotherapy. Prognostic and predictive biomarkers are lacking. We hypothesi…

…ionship of lymphocyte distribution with cell surface targets in immunotherapy, a standardized and reproducible analytical Methods is essentia…

… of the tumor microenvironment (TME) is essential for advancing immunotherapy in solid tumors. While spatial transcriptomics provides detaile…

…nt chemoimmunotherapy (with anti-PD-1/PD-L1 and anti-CTLA4) and single agent chemoimmunotherapy (with anti-PD-1/PD-L1); however, direct comparisons of these re…

… peptides and their cell of origin restriction may inform novel immunotherapy targets, and the relationship between endogenous and XPT peptid…

…the field. Moreover, it would open the possibility of utilizing immunotherapies as a means of potential strategies for cancer prevention in ind…

…une-based approaches focused on Immune Checkpoint Inhibitors or Adoptive Cell Therapies. This underscores the urgent need for a deeper, spatially resol…

…rent treatments including surgery, radiation, chemotherapy, and immunotherapy provide limited efficacy.2 Mesothelin (MSLN) is a tumor-associa…

…mor-immune interface and identify functional states relevant to immunotherapy and disease progression.References Ferri-Borgogno S, et al. Mol…

…s of the tumor microenvironment (TME) predictive of response to immunotherapy. Using a combination of protein- and RNA-based -omic technologi…